Pelvic lymph node dissection for cervical or bladder cancer: embedding residual fat tissue offers no added value

Virchows Arch. 2023 Sep;483(3):431-434. doi: 10.1007/s00428-023-03559-w. Epub 2023 May 15.

Abstract

Diagnosis of lymph node metastases in pelvic lymph node dissection (PLND) is important for staging and treatment. Standard practice is to submit visible or palpable lymph nodes for histology. We assessed the added value of embedding all residual fatty tissue.Patients (n = 85) who underwent PLND for cervical (n = 50) or bladder cancer (n = 35) between 2017 and 2019 were included. Study approval was obtained (MEC-2022-0156, 18.03.2022, retrospectively registered).The median lymph node yield with conventional pathological dissection was 21 nodes (Interquartile range (IQR) 18-28). This led to discovery of positive lymph nodes in 17 (20%) patients. Extended pathological assessment found 7 (IQR 3-12) additional nodes, but did not result in identification of more node metastases.Histopathological analysis of residual fatty tissue harvested at PLND resulted in an increased lymph node yield, but not in the detection of additional lymph node metastases.

Keywords: Bladder cancer; Cervical cancer; Metastatic lymph nodes; Pathology; Pelvic node dissection; Residual fatty tissue.

MeSH terms

  • Humans
  • Lymph Node Excision / methods
  • Lymph Nodes / pathology
  • Lymphatic Metastasis / pathology
  • Pelvis* / pathology
  • Urinary Bladder Neoplasms* / pathology
  • Urinary Bladder Neoplasms* / surgery